Risk factors
Seres Therapeutics (MCRB) risk factors
Item 1A of every Seres Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
82 risks, 8 new, 14 reworded since the prior year. Funding pressure remains central: Seres has $45.8 million cash, expects funding after Q3 2026, and discloses substantial going-concern doubt.
Filed Mar 12, 2026 - FY2024 10-K risk factors
74 risks. Seres Therapeutics faces severe going concern doubts, requiring near-term funding while advancing its clinical pipeline.
Filed Mar 13, 2025